Solifenacin treatment for overactive bladder in black patients: Patient-reported symptom bother and health-related quality of life outcomes

Current Medical Research and Opinion

Volumn 23, Issue 4, 2007, Pages 821-831

  Mallett, Veronica ^a   Burks, David ^b   Garely, Alan D ^c   Smith, Neila ^d  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

^c WINTHROP UNIVERSITY HOSPITAL   (United States)

^d ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

Black; Health related quality of life; Overactive bladder; Patient reported outcomes; Quality of life; Solifenacin; Symptom bother

Indexed keywords

SOLIFENACIN;

ADULT; AGED; ARTICLE; BLURRED VISION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOCTURIA; OVERACTIVE BLADDER; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; QUESTIONNAIRE; SELF REPORT; SYMPTOMATOLOGY; TREATMENT OUTCOME; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE; XEROSTOMIA;

ADOLESCENT; ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; QUALITY OF LIFE; QUINUCLIDINES; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE;

EID: 34247387516     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X178847     Document Type: Article

References (34)

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003;61:37-49
2. Hampel C, Wienhold D, Benken N, et al. Definition of overactive bladder and epidemiology of urinary incontinence. Urology 1997;50:4-17
3. Coyne KS, Zhou Z, Thompson C, et al. The impact on hearth-related quality of life of stress, urge and mixed urinary incontinence. Br J Urol Int 2003;92:731-5
4. Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001;76:358-63
5. Corcos J, Schick E. Prevalence of overactive bladder and incontinence in Canada. Can J Urol 2004;11:2278-84
6. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. Br J Urol Int 2001;87:760-6
7. Holroyd-Leduc JM, Straus SE. Management of urinary incontinence in women: scientific review. J Am Med Assoc 2004;291:986-95
8. Drake NL, Flynn MK, Romero AA, et al. Nocturnal polyuria in women with overactive bladder symptoms and nocturia. Am J Obstet Gynecol 2005;192:1682-6
9. Fultz NH, Herzog AR, Raghunathan TE, et al. Prevalence and severity of urinary incontinence in older African American and Caucasian women. J Gerontol A Biol Sci Med Sci 1999;54:M299-303
10. Jackson RA, Vittinghoff E, Kanaya AM, et al. Urinary incontinence in elderly women: findings from the Health, Aging, and Body Composition Study. Obstet Gynecol 2004;104:301-7
11. Brown JS, Grady D, Ouslander JG, et al. Prevalence of urinary incontinence and associated risk factors in postmenopausal women. Heart & Estrogen/Progestin Replacement Study (HERS) Research Group. Obstet Gynecol 1999;94:66-70
12. Graham CA, Mallett VT. Race as a predictor of urinary incontinence and pelvic organ prolapse. Am J Obstet Gynecol 2001;185:116-20
13. Peacock LM, Wiskind AK, Wall LL. Clinical features of urinary incontinence and urogenital prolapse in a black inner-city population. Am J Obstet Gynecol 1994;171:1464-9 [discussion 1469-71]
14. Duong TH, Korn AP. A comparison of urinary incontinence among African American, Asian, Hispanic, and white women. Am J Obstet Gynecol 2001;184:1083-6
15. Lawrence J, Lukacz E, Nager C, et al. Prevalence of female pelvis floor disorders by age and race/ethnicity among women in a managed health care population. Non-discussion poster presented at the 35th Annual Meeting of the International Continence Society, Montreal, Canada, 31 August-2 September 2005
16. Hunskaar S, Arnold EP, Burgio K, et al. Epidemiology and natural history of urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2000;11:301-19
17. Garely AD, Kaufman JM, Sand PK, et al. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Clin Ther 2006;28:1935-46
18. Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002;11:563-74
19. Matza LS, Zyczynski TM, Bavendam T. A review of quality-of-life questionnaires for urinary incontinence and overactive bladder: which ones to use and why? Curr Urol Rep 2004;5:336-42
20. Coyne KS, Matza LS, Kopp Z, et al. The validation of the Patient Perception of Bladder Condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006;49:1079-86
21. Leung HY, Yip SK, Cheon C, et al. A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder. Br J Urol Int 2002;90:375-80
22. Davila GW, Daugherty CA, Sanders SW. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001;166:140-5
23. Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003;62:237-42
24. Stach-Lempinen B, Kujansuu E, Laippala P, et al. Visual analogue scale, urinary incontinence severity score and 15 D-psychometric testing of three different health-related quality-of-life instruments for urinary incontinent women. Scand J Urol Nephrol 2001;35:476-83
25. Matza LS, Thompson CL, Krasnow J, et al. Test-retest reliability of four questionnaires for patients wih overactive bladder: the Overactive Bladder questionnaire (OAB-q), Patient Perception of Bladder Condition (PPBC), Urgency Questionnaire (UQ), and the Primary OAB Symptom Questionnaire (POSQ). Neurourol Urodyn 2005;24:215-25
26. Coyne KS, Matza LS, Thompson CL, et al. Determining the importance of change in the overactive bladder questionnaire. J Urol 2006;176:627-32
27. Sussman D, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the Antimuscarinic Clinical Effectiveness Trial (ACET). Curr Med Res Opin 2002;18:177-84
28. Homma Y, Paick JS, Lee JG, Kawabe K. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. Br J Urol Int 2003;92:741-7
29. Kelleher CJ, Cardozo LD, Khullar V, et al. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 1997;104:1374-9
30. Kobelt G, Kirchberger I, Malone-Lee J. Review. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. Br J Urol Int 1999;83:583-90
31. Shaya FT, Blume S, Gu A, et al. Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care 2005;11:S121-S129
32. McCain J. Does race have a place in biotechnological research? Biotechnol Healthcare 2005;December:54-62
33. Haab F, Cardozo L, Chappie C, Ridder AM. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005;47:376-84
34. Kelleher CJ, Cardozo L, Chapple CR, et al. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. Br J Urol Int 2005;95:81-5